Royal Bank of Canada lowered its position in shares of Agilent Technologies Inc (NYSE:A) by 18.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 224,148 shares of the medical research company’s stock after selling 51,649 shares during the period. Royal Bank of Canada’s holdings in Agilent Technologies were worth $16,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Agilent Technologies by 0.7% during the 1st quarter. BlackRock Inc. now owns 25,059,203 shares of the medical research company’s stock worth $1,794,739,000 after buying an additional 184,846 shares during the last quarter. State Street Corp increased its holdings in shares of Agilent Technologies by 0.4% during the 1st quarter. State Street Corp now owns 13,574,513 shares of the medical research company’s stock worth $974,623,000 after buying an additional 50,304 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Agilent Technologies by 7.6% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,716,098 shares of the medical research company’s stock worth $487,640,000 after buying an additional 402,021 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Agilent Technologies by 4.8% during the 1st quarter. Invesco Ltd. now owns 5,018,454 shares of the medical research company’s stock worth $359,422,000 after buying an additional 228,244 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Agilent Technologies by 2.0% during the 1st quarter. Geode Capital Management LLC now owns 4,950,997 shares of the medical research company’s stock worth $353,910,000 after buying an additional 95,831 shares during the last quarter.

A number of analysts have recently issued reports on the stock. UBS Group raised their price target on shares of Agilent Technologies from $84.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, May 22nd. Wells Fargo & Co increased their price objective on shares of Agilent Technologies from $82.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. Bank of America increased their price objective on shares of Agilent Technologies from $74.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, May 22nd. SVB Leerink increased their price objective on shares of Agilent Technologies from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, May 22nd. Finally, Stifel Nicolaus lowered their price objective on shares of Agilent Technologies from $85.00 to $73.00 and set a “hold” rating for the company in a research report on Thursday, April 2nd. Eleven analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $85.75.

In other news, CEO Michael R. Mcmullen sold 13,603 shares of Agilent Technologies stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $78.72, for a total transaction of $1,070,828.16. Following the completion of the sale, the chief executive officer now directly owns 529,245 shares of the company’s stock, valued at approximately $41,662,166.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 8,814 shares of Agilent Technologies stock in a transaction on Monday, April 27th. The stock was sold at an average price of $76.20, for a total transaction of $671,626.80. Following the sale, the chief executive officer now directly owns 542,848 shares of the company’s stock, valued at $41,365,017.60. The disclosure for this sale can be found here. Insiders sold a total of 64,426 shares of company stock valued at $5,300,943 in the last three months.

Shares of A stock opened at $85.90 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.63 and a debt-to-equity ratio of 0.38. Agilent Technologies Inc has a 52 week low of $61.13 and a 52 week high of $93.04. The stock has a market capitalization of $26.94 billion, a PE ratio of 39.59, a P/E/G ratio of 2.81 and a beta of 1.13. The firm has a 50 day moving average of $85.74 and a two-hundred day moving average of $81.58.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Thursday, May 21st. The medical research company reported $0.71 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.10. Agilent Technologies had a net margin of 13.04% and a return on equity of 20.76%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter last year, the company posted $0.71 EPS. The firm’s revenue was up .2% compared to the same quarter last year. Analysts expect that Agilent Technologies Inc will post 3.11 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th will be given a $0.18 dividend. The ex-dividend date is Monday, June 29th. This represents a $0.72 annualized dividend and a yield of 0.84%. Agilent Technologies’s dividend payout ratio is presently 23.15%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Further Reading: Recession

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.